Mentioned in ?
References in periodicals archive ?
Caption: Figure 2: miR-362 promotes NSCLC metastasis in vitro and in vivo.
Reportedly, the MAAv submission is based on data from the Phase III FLAURA trial, in which Tagrisso significantly improved progression-free survival (PFS) compared to current 1st-line EGFR-TKIs, erlotinib or gefitinib, in previously-untreated patients with locally-advanced or metastatic EGFRm NSCLC.
"We are pleased to expand our collaboration with Calithera into NSCLC and melanoma, building upon our existing clinical study evaluating Opdivo and CB839 in clear cell renal cell carcinoma," said Fouad Namouni, M.D., senior vice president, head of Oncology Development, Bristol-Myers Squibb.
And the biological and clinical data of NSCLC patients (age and sex/Agenda, body mass index, blood pressure, tumor-related, and pathological data) in the duration of hospitalization was collected and reviewed; the incidence of DVT and tumor metastasis at the time of diagnosis was calculated to evaluate the disease conditions of in-hospital NSCLC patients.
The overall goal of our research is to find new genetic drivers in NSCLC that might lead to new targets for therapy.
Herein we examine the cost and clinical impact of EGFR and ALK testing of patients with early-stage NSCLC. To our knowledge, this is the first study to incorporate a cost analysis in assessing whether universal EGFR mutation and ALK rearrangement testing in NSCLC is warranted.
The NSCLC pipeline is large and diverse, with an increased presence of mAbs and specific targeted therapies in contrast to the market -
Conclusion: These results showed similar disease-free survival rates of DP and GP therapies in one and two years after surgery for NSCLC. However, DP group exhibited higher incidence of grade III-IV thrombocytopenia and alopecia than GP group.
In addition, the influence of miR-222 on the prognosis of NSCLC patients was estimated.
They found that JHQG helped to prolong survival in patients with metastatic NSCLC compared with patients receiving standard care; was safe and effective in the management of IPF and could also help improve patients' quality of life and activity capacity; and helped to reduce fever in patients with influenza compared with placebo.
With the NCI funding, we hope to establish in vivo proof of concept for NSCLC. This will set the stage for the development of new therapies for not only NSCLC but also other inflammation-associated cancers such as pancreatic and colon cancers, thereby leading to a higher survival rate of the patients.”
He added that the Moffitt researchers are confident that their newly tested malignancy-risk gene signature for NSCLC will provide that tool because their malignancy-risk gene signature is a proliferative gene signature, one associated with both cancer risk and progression.
Medical browser ?
Full browser ?